Influenza Related Illness/Influenza Virus

The influenza vaccine is less effective in the elderly. It is unknown whether influenza vaccination of nonelderly adults confers additional disease protection on the elderly population.  In a large, nationwide sample of Medicare beneficiaries, influenza vaccination among adults aged 18–64 years was inversely associated with illnesses related to influenza in the elderly. This year, the global market for products used in the fight against influenza will be worth an estimated $5.5 billion, according to a new technical market research report, the Global Influenza Market, from BCC Research. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.

    Related Conference of Influenza Related Illness/Influenza Virus

    Influenza Related Illness/Influenza Virus Conference Speakers